“Oppenheimer: These 2 Stocks Could Double, If Not More”
October 21, 2020
“NeuBase Therapeutics (NBSE)…
Are other analysts in agreement? They are. Only Buy ratings, 4 to be exact, have been issued in the last three months. Therefore, the message is clear: NBSE is a Strong Buy. Given the $16.50 average price target, shares could soar 97% in the next year…
Prevail Therapeutics (PRVL)…
All in all, other analysts echo Olson’s sentiment. 5 Buys and no Holds or Sells add up to a Strong Buy consensus rating. With an average price target of $23.25, the upside potential comes in at 139%…”
https://finance.yahoo.com/news/oppenheimer-2-stocks-could-double-140951844.html